OLGX News Alert

Osteologix to Present at the Acumen BioFin Rodman and Renshaw 9th Annual Healthcare Conference
Tuesday October 30, 4:16 pm ET

Live Webcast Scheduled November 5 at 12:20 p.m. ET

SAN FRANCISCO--(BUSINESS WIRE)--Osteologix Inc. (OTC BB: OLGX.OB), a specialty pharmaceutical company developing innovative therapies for the treatment and prevention of musculoskeletal diseases, today announced that Philip J. Young, President and CEO of Osteologix, will present a corporate overview Monday, November 5, at 12:20 p.m. EST during the Rodman and Renshaw Acumen BioFin 9th Annual Healthcare Conference at the New York Palace Hotel in New York City. A live audio webcast and slide presentation will be available via the internet by visiting www.osteologix.com and clicking the link provided under ?Latest News?. An archived presentation will be available for 90 days.

About Osteologix

Osteologix is a specialty pharmaceutical company committed to developing innovative therapies for the treatment and prevention of musculoskeletal diseases. The Company?s vision is to improve the health of those afflicted with musculoskeletal diseases such as osteoporosis. Its lead product candidate, NB S101, is a novel pharmaceutical agent for the treatment and prevention of osteoporosis. For more information please visit www.osteologix.com.

About NB S101

NB S101 is a novel dual acting bone agent, or DABA, the active component of which significantly improves bone density and reduces fracture risk. In preclinical studies, NB S101 has demonstrated significant beneficial effects by reducing bone resorption and increasing bone formation and bone mineralization. This dual action on bone? a significant medical need? suggests that NB S101 could fundamentally change the treatment paradigm of patients with osteoporosis. Importantly, NB S101 helps to build bone in a manner similar to the body?s own metabolic processes by rebalancing bone metabolism in a way that favors strong bone development. Osteologix has a competitive intellectual property position. A key patent for NB S101 has been issued in EU providing protection out to 2024, with US patents published and currently pending.

The NB S101 Program and the STRONG Study

Osteologix has conducted extensive preclinical and clinical drug research with its proprietary DABA, NB S101. The Phase II STRONG Study evaluating NB S101 is a randomized, double-blind, placebo-controlled, parallel-group dose response study in 289 postmenopausal women. The results will provide data on the effects of NB S101 on bone metabolism, bone mineral density, safety, tolerability and pharmacokinetics. The primary endpoint in the trial is the change in patients' bone resorption, as measured by the biochemical marker CTX-1. Data from this trial will be reported in the fourth quarter of 2007.

For Further Information, Contact:
RedChip Companies, Inc.
541 S. Orlando Avenue, Suite 206, Orlando, FL 32751, (800) 733-2447,
Fax: (407) 644-0758, info@redchip.com